帕利哌酮缓释片治疗精神分裂症临床观察  

Study on Paliperidone Extended-release Tablets in the Treatment of Schizophrenia

作　　者：罗瑜[1] 张霞[1] 周健[1] 

机构地区：[1]中国.江苏省无锡市精神卫生中心,214151

出　　处：《中国健康心理学杂志》2012年第10期1591-1592,共2页China Journal of Health Psychology

摘　　要：目的探讨帕利哌酮缓释片治疗精神分裂症的疗效和安全性。方法对50例精神分裂症患者进行为期8周的帕利哌酮缓释片治疗,在治疗期间定期进行阳性与阴性症状量表(PANSS)、副反应量表(TESS)评定及血常规、心电图、血生化检查。结果帕利哌酮缓释片治疗前后PANSS评分差异有统计学意义(t=19.6,P<0.01),常见的不良反应是失眠、头痛和锥体外系反应(EPS)。结论帕利哌酮缓释片能有效治疗精神分裂症,安全性好。Objective To explore the efficacy and safety of paliperidone extended-release tablets（paliperidone ER）in the treatment of schizophrenia.Methods A total of 50 patients with schizophrenia received 8-week paliperidone ER treatment.PANSS and TESS were used to assess patients,and blood routine,ECG and biochemistry were tested periodically.Results The scores of PANSS decreased significantly compared to the baseline after treatment（t=19.6,P0.01）.The common adverse events were insomnia,headache and EPS.Conclusion Paliperidone ER is effective and safe in the treatment of schizophrenia.

关 键 词：精神分裂症 帕利哌酮缓释片 疗效 安全性 

分 类 号：R749.3[医药卫生—神经病学与精神病学]